Literature DB >> 24814412

The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view.

Marijke de Vries1, Boudewijn Klop1, Manuel Castro Cabezas2.   

Abstract

Current guidelines for the management of dyslipidaemias recommend measuring lipid profiles in the fasting state. The primary lipid targets are traditionally plasma total cholesterol and low-density lipoprotein-cholesterol (LDL-C) levels. However, triglycerides, apolipoprotein (apo) B and non-high-density lipoprotein-cholesterol (non-HDL-C) are also suitable parameters to assess cardiovascular risk and to guide lipid-lowering therapy. The advantage of the use of these variables is that they can be used in both the fasting and non-fasting state. In most cases, postprandial lipid profiles in combination with apo B are as useful as fasting lipid profiles for the differentiation between familial lipid disorders, such as heterozygous familial hypercholesterolemia, familial combined hyperlipidemia and familial hypertriglyceridemia. This article will address the interpretation, applications and limitations of a non-fasting lipid profile for daily clinical practice.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apolipoprotein B; Non-HDL-C; Non-fasting triglycerides

Mesh:

Substances:

Year:  2014        PMID: 24814412     DOI: 10.1016/j.atherosclerosis.2014.03.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

2.  Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists: An update.

Authors:  Yazid N Al Hamarneh; Sherilyn K D Houle; Raj Padwal; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

3.  Is it time to break the fast?-a paradigm shift in clinical lipidology.

Authors:  Manuel Castro Cabezas; Benjamin Burggraaf; Boudewijn Klop
Journal:  Ann Transl Med       Date:  2016-11

4.  Prenatal Docosahexaenoic Acid Supplementation Does Not Affect Nonfasting Serum Lipid and Glucose Concentrations of Offspring at 4 Years of Age in a Follow-Up of a Randomized Controlled Clinical Trial in Mexico.

Authors:  Yareni Gutierrez-Gomez; Aryeh D Stein; Usha Ramakrishnan; Albino Barraza-Villarreal; Hortensia Moreno-Macias; Carlos Aguilar-Salinas; Isabelle Romieu; Juan A Rivera
Journal:  J Nutr       Date:  2016-12-21       Impact factor: 4.798

5.  Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Authors:  Dirk Müller-Wieland; Lawrence A Leiter; Bertrand Cariou; Alexia Letierce; Helen M Colhoun; Stefano Del Prato; Robert R Henry; Francisco J Tinahones; Lisa Aurand; Jaman Maroni; Kausik K Ray; Maja Bujas-Bobanovic
Journal:  Cardiovasc Diabetol       Date:  2017-05-25       Impact factor: 9.951

6.  Non-fasting lipids detection and their significance in pregnant women.

Authors:  Yulong Li; Jianxun He; Xiaoli Zeng; Song Zhao; Xuebing Wang; Hui Yuan
Journal:  Lipids Health Dis       Date:  2019-04-11       Impact factor: 3.876

7.  Threshold Effects in the Relationship Between Serum Non-High-Density Lipoprotein Cholesterol and Metabolic Syndrome.

Authors:  Saibin Wang; Junwei Tu; Yibin Pan
Journal:  Diabetes Metab Syndr Obes       Date:  2019-11-29       Impact factor: 3.168

8.  Non-HDL-C Is More Stable Than LDL-C in Assessing the Percent Attainment of Non-fasting Lipid for Coronary Heart Disease Patients.

Authors:  Li-Ling Guo; Yan-Qiao Chen; Qiu-Zhen Lin; Feng Tian; Qun-Yan Xiang; Li-Yuan Zhu; Jin Xu; Tie Wen; Ling Liu
Journal:  Front Cardiovasc Med       Date:  2021-04-01

9.  Serum non-high-density lipoprotein cholesterol is associated with the risk of sudden sensorineural hearing loss.

Authors:  Saibin Wang; Qian Ye; Yibin Pan
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.